Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma

NCT01688973 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01688973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01688973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 20, 2012
Completion date
April 30, 2017
Enrollment
55 (actual)
Sites
214

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent renal cell carcinoma, stage iii renal cell cancer, stage iv renal cell cancer, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma